You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

CLINICAL TRIALS PROFILE FOR PROTONIX


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Protonix

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00133770 ↗ Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2004-07-01 The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00133770 ↗ Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed Emory University Phase 4 2004-07-01 The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00206050 ↗ Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po Completed AstraZeneca Phase 4 2004-09-01 This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
NCT00625274 ↗ A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients Completed AstraZeneca Phase 4 2004-06-01 This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).
NCT00674245 ↗ Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD. Completed Southern Arizona VA Health Care System Phase 2/Phase 3 2008-04-01 The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Protonix

Condition Name

Condition Name for Protonix
Intervention Trials
Healthy 10
Gastroesophageal Reflux 2
Proton Pump Inhibitor Allergy 2
Healthy Adults 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Protonix
Intervention Trials
Gastroesophageal Reflux 5
Malnutrition 3
Psychotic Disorders 2
Mental Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Protonix

Trials by Country

Trials by Country for Protonix
Location Trials
United States 21
Canada 9
India 6
Saudi Arabia 1
Bosnia and Herzegovina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Protonix
Location Trials
Missouri 4
Texas 3
Wisconsin 2
California 2
Nebraska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Protonix

Clinical Trial Phase

Clinical Trial Phase for Protonix
Clinical Trial Phase Trials
Phase 4 7
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Protonix
Clinical Trial Phase Trials
Completed 20
Terminated 3
Withdrawn 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Protonix

Sponsor Name

Sponsor Name for Protonix
Sponsor Trials
Mirati Therapeutics Inc. 2
AstraZeneca 2
Kremers Urban Development Company 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Protonix
Sponsor Trials
Industry 22
Other 20
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.